Boehringer Ingelheim Limbering Up With Humira Biosimilar

 
• By Eleanor Malone

Presenting equivalence data at EULAR for its biosimilar version of the world's best-selling drug, Humira, Boehringer Ingelheim is optimistic about its position in a crowded field. Karsten Kissel, head of global medical affairs biosimilars for the German group, spoke to Scrip.

Races
Boehringer Ingelheim early to gates in crowded field • Source: Shutterstock

More from Business

More from Scrip